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The TCR repertoire 
of α‑synuclein‑specific T 
cells in Parkinson’s disease 
is surprisingly diverse
Akul Singhania1, John Pham1, Rekha Dhanwani1, April Frazier1, Juliana Rezende Dutra2, 
Karen S. Marder2, Elizabeth Phillips3,4, Simon Mallal3,4, Amy W. Amara5, David G. Standaert5, 
David Sulzer2,6,7, Bjoern Peters1,8, Alessandro Sette1,8 & Cecilia S. Lindestam Arlehamn1*
The self‑antigen α‑synuclein (α‑syn) was recently shown to be associated with Parkinson’s disease 
(PD). Here we mapped the T cell receptor (TCR) repertoire of α‑syn‑specific T cells from six PD patients. 
The self‑antigen α‑syn‑specific repertoire was compared to the repertoire of T cells specific for 
pertussis (PT), as a representative foreign antigen that most individuals are exposed to, revealing that 
the repertoire for α‑syn was as diverse as the repertoire for PT. The diversity of PT‑specific clonotypes 
was similar between individuals with PD diagnosis and age‑matched healthy controls. We found that 
the TCR repertoire was specific to each PD patient, and no shared TCRs among patients were defined, 
likely due to differences in HLA expression that select for different subsets of epitope‑specific TCR 
rearrangements. This study provides the first characterization of α‑syn‑specific TCR clonotypes in 
individuals with PD. Antigen‑specific TCRs can serve as immunotherapeutics and diagnostics, and 
means to track longitudinal changes in specific T cells, and disease progression.
Recognition of T cell epitopes is dependent on the expression of specific HLA molecules that bind the peptides 
and the presence of T cells expressing specific T cell receptors (TCRs). TCRs are generated by somatic recom-
bination during lineage development. The theoretically possible combinatorial diversity of the TCR repertoire 
has been estimated to be > 1015 distinct αβ receptors or  clonotypes1, which is many more sequence combinations 
than the number of T cells in an  individual2. The actual repertoire that emerges after the processes of positive and 
negative selection is much more restricted, as many of the potentially autoreactive TCRs are  eliminated3. We and 
others have shown that the presence of a precursor repertoire of naïve T cells capable of recognizing an epitope 
is a good predictor of the magnitude of response against an  epitope4–7. The CDR3 region of the TCR-β chain is 
the most polymorphic and makes direct contact with the epitope, and sequencing of this region is sufficient to 
generate a marker of epitope-specific T cells.
In humans, the development of immune responses in infection, vaccination, and disease results in the selec-
tive expansion of specific T  cells3. In the setting of autoimmune disease and non-mutated cancer antigens, the 
TCR repertoire of epitope-reactive T cells is thought to be significantly less  diverse8, as high affinity TCR clones 
are thought to be eliminated and inactivated by thymic education, as well as central and peripheral  tolerance3.
We previously described that individuals with Parkinson’s disease (PD) possess T cells that recognize specific 
epitopes derived from the PD associated protein α-synuclein (α-syn)9, indicating the presence of autoimmune 
features in this disease. Recently, we found that α-syn-reactive T cells are most abundant immediately after diag-
nosis of motor PD and may be present years before the diagnosis of motor  PD10. In contrast to the case of PT, and 
in accordance with the notion that the autoimmune repertoire is narrowed by thymic selection, the responses 
to α-syn are weaker, requiring an in vitro amplification step to be detected. Moreover, this is consistent with the 
relatively small size of α-syn, which contains two main epitope  regions9.
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Here we studied the TCR repertoire of α-syn T cells from PD patients and compared it to the repertoire of 
T cells specific for PT (aP vaccine antigens) as a control. We further examined whether the increased frequency 
of T cells responding to specific α-syn epitopes in PD subjects is associated with the presence of shared ‘public’ 
TCRs in PD patients recognizing these epitopes. As expected based on the wide diversity of HLA that select for 
different subsets of epitope specific TCR rearrangements in the population, we found that the α-syn-specific TCR 
repertoire differed among PD patients. We did not find any public TCRs, but rather we found that the TCR rep-
ertoire directed to the self-antigen α-syn was as diverse as the TCR repertoire directed to the foreign PT antigens.
Results
Similar numbers of clonotypes expand upon stimulation with α‑syn and PT peptide pools. We 
have previously described the identification of α-syn and PT reactive T  cells9,11. Briefly, to detect relatively rare 
antigen-specific CD4 T cells, like α-syn-specific T cells, PBMCs were stimulated for 14 days in vitro with epitope 
pools for α-syn or PT. After two weeks, cultures were harvested and stimulated with epitope pools, and ana-
lyzed for cytokine production in a triple-color IFNγ, IL-5 and IL-10 Fluorospot assay. In this study we tested 20 
individuals with PD for T cell reactivity against α-syn and PT, as well as 55 age-matched HC against PT (Fig. 1). 
We assumed that the vast majority of individuals in our cohort above 45 years of age will have been exposed to 
or vaccinated against PT. As expected, 65/75 individuals responded to the PT peptide pool. Additionally, the 
magnitude of response against PT was significantly higher (two-tailed Mann–Whitney p = 0.0002) than that for 
α-syn-specific responses (Fig. 1). No difference was observed in the magnitude of response against PT when 
comparing PD with age-matched HC (two-tailed Mann–Whitney p = 0.73) (Fig. 1). HC were not tested for α-syn 
reactivity, as the α-syn reactivity is specific for PD, and HC react only occasionally and with significantly lower 
 magnitude9.
For TCR sequencing, we selected 6 of the individuals with PD who had α-syn-specific T cell reactivity as 
determined by the Fluorospot assay (Fig. 1, red symbols; Table 1) and 7 age-, sex-, and recruitment site-matched 
HC (Fig. 1, red symbols; Table 1). PBMC cultures, 2 million PBMCs were cultured per replicate, were harvested 
and DNA was purified for TCR sequencing using the ImmunoSEQ service from Adaptive Biotechnologies. Each 
sample included a culture replicate and as a comparison, the ex vivo repertoire of CD4 T cells was determined. 
The productive repertoire of each sample, i.e., the unique in-frame rearrangements that do not contain a stop 
codon, and the frequency of these productive clonotypes within the sample was assessed. The number of clo-
notypes covering eighty percent of the productive repertoire was similar between replicates of the same sample 
(Fig. 2a, b). In PD, the number of clonotypes contributing to the productive repertoire was similar upon stimula-
tion with either the α-syn or PT peptide pools (Fig. 2a). In HC, however, a wider number of clonotypes covering 
eighty percent of the productive repertoire following stimulation with PT peptides (Fig. 2b). As expected, all 
donors exhibited a decrease in the number of productive rearrangements as a result of stimulation when com-
pared to the ex vivo samples (Fig. 2a, b), suggesting the selection and expansion of specific clonotypes upon 
stimulation with peptide pools, leading to fewer unique rearrangements within the sample.
Stimulation with α‑syn and PT leads to the expansion of specific clonotypes. We next explored 
the repertoire of α-syn- or PT-specific clonotypes in our samples. To this end, we compared the productive rep-
ertoire of samples stimulated with the peptide pools to the corresponding ex vivo CD4 samples, and identified 
clonotypes that were significantly perturbed as a result of either α-syn or PT stimulation (Table 2 and Supple-
mentary Fig. 1). As expected, of the clonotypes that were significantly perturbed upon stimulation, the majority 
expanded and had higher frequencies compared to the ex vivo CD4 samples (Supplementary Fig. 1).
Figure 1.  Magnitude of responses against α-syn and PT peptides. Magnitude of responses (sum of IFNγ, IL-5, 
and IL-10) against α-syn and PT peptides as SFC per  106 cultured PBMC (14-day in vitro expansion). Each 
point and symbol represents one participant. Red symbols indicate participants that were selected for TCR 
sequencing. Median ± interquartile range is shown.
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In our assays, we included replicate samples to allow identification of the clonotypes that reproducibly 
expanded within a single donor. Similar numbers of clonotypes were significantly expanded in each of the 
replicate samples from a donor (− log2 OR > 1 and FDR p val < 0.05 in both replicates; Table 2, Fig. 3a–c, and 
Supplementary Fig. 1). For α-syn stimulated samples an average of 176 clonotypes per replicate was found. In the 
case of PT stimulated samples, we found similar number of expanded clonotypes per replicate when comparing 
the two different cohorts, with an average of n = 186 clonotypes per replicate in PD and an average of n = 200 
in HC. On average, the common clonotypes between the replicates corresponded to 30% of the total expanded 
clonotypes in the donor (ranging from 15 to 55%; Table 2, Fig. 3a–c).
Stimulation with α‑syn or PT results in participant‑specific TCR expansion. Having determined 
the overlap between replicates in in vitro stimulated cultures, we next investigated whether repertoire overlap 
was detected between the 6 different PD subjects or the 7 different HC subjects. Based on the exact clonotype 
rearrangement sequence, none of the clonotypes identified by α-syn or PT stimulation were observed across all 
individuals, suggesting that the various subjects are associated with different individual repertoires (Supplemen-
tary Fig. 2).
We also assessed overlap between individuals using the GLIPH  algorithm12, which clusters TCR sequences 
based on similarities in enrichment for either 3-/4-mers, convergence groups (a set of multiple TCRs from one 
or more individuals that bind the same antigen in a similar manner through similar TCR contacts), global con-
vergence (a pair of TCRs that share the same length CDR3 and differ by less than 1 amino acid in those CDR3 
regions), and local convergence (a pair of TCRs that share in their CDR3 regions an amino acid motif that appears 
enriched in their sample set). The GLIPH analysis revealed that there was higher similarity between replicate 
samples within a single individual and essentially no overlap across individuals (Supplementary Table 1). The gen-
eral lack of overlap also reflects the HLA class II allele diversity in the test population (Supplementary Table 2).
Table 1.  Summary of demographic characteristics of enrolled participants.
Total cohort
Individual PD participants accessed by TCR 
sequencing Total cohort Individual HC participants accessed by TCR sequencing
Characteristics PD 3450 3460 3486 3489 3529 3530 HC 3447 3452 3457 3459 3466 3487 3495
Participants enrolled, n 20 55
Age, median, range, 
years 58.5 (51–73) 58 51 73 62 55 57 66 (53–92) 56 53 55 60 70 69 57
Sex, male, % (n) 60 (12) M F F M M F 49 (27) F F M M M F M
Caucasian, % (n) 95 (19) White White White White White Asian 93 (51) White White White White White White White
Age at diagnosis of PD, 
median, range, yr 55.5 (48–72) 54 50 72 60 54 57 N/A – – – – – – –
Years since diagnosis, 
median, range, yr 1 (0–4) 4 1 1 2 1 0 N/A – – – – – – –
UPDRS, median, range 24.5 (12–37) 28 12 23 37 26 16 N/A – – – – – – –
MoCA, median, range 25.5 (21–28) 28 27 28 21 24 23 N/A – – – – – – –
LED, median, range 250 (0–450) 400 450 0 450 100 0 N/A – – – – – – –
Total SFC (α-syn, sum of 
IFNγ, IL-5 and IL-10) – 1057 2950 460 2097 2103 3200 – – – – – – – –
Total SFC (PT, sum of 
IFNγ, IL-5 and IL-10) – 100 3278 8947 14,620 7330 8087 – 1167 1367 2323 4350 14,900 1257 11,987
Figure 2.  Similar number of clonotypes expand in response to α-syn and PT peptide pools. Number of TCR 
clonotypes covering 80% of the productive repertoire. Ex vivo CD4 repertoire (blue) captured immediately 
following thaw. Two replicates (red and yellow) were sequenced for each peptide pool stimulation (14-day 
in vitro expansion). Each point and symbol represents one participant. a PD n = 6, b HC n = 7.
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Table 2.  Clonotypes expanded upon stimulation with α-syn or PT peptides.
Specificity Cohort Participant
Total no. of clonotypes 
(replicate 1/2)
No. of expanded clonotypes 
(replicate 1/2)
No. of expanded clonotypes in 
both replicates (% of expanded 
repl. 1/2)
No. of antigen-specific 




3450 25,885/21,702 231/278 56 (24/20) 16 (29)
3460 8772/5497 124/67 19 (15/28) 5 (26)
3486 36,306/25,617 190/122 48 (25/39) 15 (31)
3489 19,383/20,466 199/197 67 (34/34) 17 (25)
3529 13,444/16,356 136/137 33 (24/24) 9 (27)
3530 24,402/17,858 225/204 49 (22/24) 13 (27)
PT
3450 23,999/20,713 287/226 61 (21/27) 23 (38)
3460 6695/7273 78/70 17 (22/24) 3 (18)
3486 12,934/16,804 93/108 30 (32/28) 5 (17)
3489 16,772/18,366 258/264 75 (29/28) 20 (27)
3529 24,283/27,116 122/135 48 (39/36) 17 (35)
3530 12,932/16,636 269/319 47 (17/15) 17 (36)
PT HC
3447 65,296/64,818 135/134 56 (41/42) –
3452 60,026/64,994 270/239 45 (17/19) –
3457 56,571/58,480 299/363 121 (40/33) –
3459 37,002/41,917 194/143 78 (40/55) –
3466 30,810/29,033 241/221 112 (46/51) –
3487 64,542/61,252 123/127 50 (41/39) –
3495 28,371/26,341 122/182 37 (30/20) –
Figure 3.  Similar numbers of expanded clonotypes in response to α-syn and PT stimulation. The number 
of expanded clonotypes in α-syn- and PT-stimulated PD (a, b) and HC (c) samples. For PD both absolute 
numbers (top) and normalized against total number of clonotypes in each replicate (bottom) is shown. Red 
indicates clonotypes that are unique in replicate 1, yellow indicates clonotypes that are unique in replicate 2. 
Grey indicates clonotypes that are common between the two replicates (− log2 OR > 1 and FDR p val < 0.05) and 
dark grey indicates antigen-specific clonotypes, i.e., number and proportion of clonotypes that expanded only 
in each antigen-stimulated culture excluding clonotypes that expanded irrespective of stimuli. d Percentage of 
α-syn- and PT specific clonotypes in PD (dark grey in bottom graphs). Yellow (replicate 1) and blue (replicate 2). 
Mean ± StDev is shown. Paired two-tailed t test.
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Definition of α‑syn‑ or PT‑specific clonotypes. To capture clonotypes that were specifically altered as 
a result of α-syn stimulation and not due to effects associated with non-specific bystander activation in in vitro 
culture, we compared the clonotypes significantly expanded in response to α-syn stimulation with those that 
significantly expanded following PT stimulation in the PD participants. We focused on reproducible clonotypes 
identified in both replicate samples following stimulation with α-syn (Table 2, Supplementary Fig. 1b). Of these 
reproducible clonotypes (Fig. 3a, light gray bars), approximately 30% (25–31%) were specifically altered upon 
α-syn stimulation and not by PT stimulation (Fig. 3a, dark gray bars, Supplementary Fig. 1c).
Next, we assessed whether these α-syn-specific clonotypes (Fig. 3a, dark gray bars) had a higher expansion 
indicating a larger selection, compared to those clonotypes that were also reproducible between the two replicates, 
but were non-specific. To assess this, we determined the total templates of each of the α-syn-specific clonotypes 
and whether these templates corresponded to a higher frequency in the overall reproducible clonotype pool 
identified in both replicates (α-syn-specific + non-specific). On average, α-syn-specific clonotypes (which made 
up 30% of the reproducible clonotype pool) had an overall frequency of 28%, and the non-specific clonotypes 
(which made up 70% of the reproducible clonotype pool) had a frequency of 72% (Fig. 4a). This indicates a 
similar expansion and selection between these two clonotype groups.
Similar to the α-syn expansion, following PT stimulation (Table 2, Supplementary Fig. 1b), approximately 
30% (17–38%) of the clonotypes were specifically altered upon PT stimulation in both replicates within a donor 
(Fig. 3b, Supplementary Fig. 1c). There were no significant differences in the number of antigen-specific clono-
types expanded in response to α-syn or PT stimulation (Fig. 3d). However, in contrast to the α-syn-specific clono-
types, on average these PT-specific clonotypes made up 48% of the frequency of the total reproducible clonotype 
pool, suggesting a greater expansion and selection of these clonotypes compared to the non-specific clonotypes 
that had a frequency of 52% (Fig. 4b). There was a trend toward the specific clonotype expansion against α-syn 
being more limited than that against PT (Fig. 4c), which may reflect general differences in response to foreign 
and self-antigens. However, this increased expansion of PT-specific clonotypes compared to the α-syn-specific 
clonotypes was true for some individuals, but not all (Fig. 4c).
Figure 4.  α-Syn-specific clonotypes have a similar frequency to the overall expanded clonotypes. Frequency of 
clonotypes expanded upon α-syn (a) or PT (b) stimulation in both replicates (excluding non-specific expansion 
in response to both stimuli conditions) in the total productive repertoire (normalized to respective combined 
total) in individual PD participants. c Percentage frequency of the expanded antigen-specific clonotypes for 
α-syn and PT. Yellow and blue indicates individual replicates. Mean ± StDev is shown. Paired two-tailed t-test.
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Discussion
Here we report an analysis of PD patients in regard to the α-syn-specific TCR repertoire, an autoantigen recently 
associated with  PD9,13 and its  progression10. The rationale for this analysis originates from the fact that detection 
of TCRs specifically associated with PD might provide a diagnostic tool, could generate insights into disease 
pathogenesis, and pave the way for adoptive transfer applications.
In terms of the potential for TCR-based diagnostics, our study demonstrates that TCRs can be mapped to 
α-syn responses in PD patients. Our stringent selection criteria of only focusing on clonotypes present in rep-
licate samples identifies the TCRs that are antigen-specific, and may not identify the complete antigen-specific 
repertoire within an individual. Previous  studies12,14 have found that within an epitope-specific repertoire, a por-
tion of the responding receptors cluster closely together based on shared motifs. To find shared TCR clonotypes 
between individuals, we used direct sequence comparison, and the GLIPH  algorithm12 applied to the clonotypes 
identified in two replicates. We did not find evidence for shared TCR repertoires for either α-syn or PT in the 
subjects studied, similar to findings for individuals with  MS15. There are limited studies on autoantigen-specific 
TCR repertoires. However, in a study by Eugster et al., where they investigated the TCR repertoire of GAD65 
autoantigen-specific human CD4 T cells, they also found high diversity in the  repertoire16. These findings are not 
surprising, as these subjects were not matched based on their HLA expression. The response to α-syn, like any 
other known human antigens, is mediated by multiple epitopes, so that different individuals typically respond 
to different epitopes, which are restricted by diverse HLA alleles. While shared epitope-specific receptor chains 
have been observed in individuals sharing the relevant HLA  alleles17,18, this is relatively uncommon and does not 
appear to be the case for PD associated α-syn-specific TCRs. Thus, while the present study provides a proof of 
concept for the definition of PD associated α-syn-specific TCRs, further studies of HLA-matched individuals with 
larger numbers of subjects will be required to thoroughly address diagnostic utility. Moreover, the involvement of 
α-syn-specific T cell responses and associated α-syn-specific TCRs can be investigated in other synucleinopathies 
such as multiple system atrophy (MSA) and dementia with Lewy Bodies (DLB).
The present study represents individual antigen-specific repertoires that can be considered as a sampling 
from the possible collective repertoire. There is limited data on similar sequences within a collective repertoire 
i.e., pooling of sequences from multiple  individuals19.
It is noteworthy that clustered TCRs may be present due to an evolutionary focusing on particular epitopes, 
as they have primarily been described in the responses to pathogens that have coexisted with humans for long 
evolutionary periods, such as herpesviruses and Mycobacterium tuberculosis12,17.
To compare the specificity of TCR response in PD, we examined the TCR repertoires associated with α-syn 
responses to those associated with PT. PT is a foreign antigen and we measured responses against the epitopes 
from the antigens contained in the acellular Pertussis vaccine, from which 132 epitopes have been  defined11. 
Vaccination and boosting with the TDaP vaccine (PT in combination with tetanus and diphtheria) is ubiquitous, 
most individuals receives multiple booster immunizations throughout life, and therefore most human subjects 
exhibit a vigorous T cell response to this PT peptide  pool11,20. This is in contrast to influenza, where the vaccine 
composition and peptide epitopes change every year, or to other ubiquitous pathogens (such as CMV) where 
responsiveness is dependent on the individuals being chronically infected. Furthermore, the PT peptide pool is 
associated with HLA class II restricted CD4 responses, like α-syn, and it has been extensively  characterized11,20–23. 
α-Syn, in contrast, is a small self-antigen with only 11 defined T cell epitopes, and so we expected to find a 
much narrower repertoire for α-syn. Surprisingly, we found that the TCR repertoire for α-syn-specific T cells 
is as restricted as that of PT-specific T cells, and concomitantly we found no difference in the PT-specific TCR 
repertoire between PD and HC. α-Syn brain pathology is quite common in older adults and it is difficult to know 
whether a HC will go on to develop PD in the future. For this reason, we did not compare α-syn-specific responses 
between the cohorts, instead focusing on α-syn-specific clonotypes in comparison with PT. The result that the 
α-syn and PT repertoire are similar is surprising, given the inherent differences in terms of nature of exposure, 
and number of epitopes available. It should be noted that the size of the PT repertoire is likely a reflection of 
repeated vaccine boosting and multiple re-exposures over an individual’s lifespan. It is possible that the overall 
similar complexity of TCRs might reflect repeated (in the case of PT), or chronic (in the case of α-syn) exposure 
and stimulation, progressively narrowing the repertoire to a similar degree.
In terms of the potential for adoptive therapy, it has been hypothesized that α-syn TCRs can be cloned into 
“suppressive” IL-10 producing T cells, thus providing a counter balance to proinflammatory  responses24. Our 
study suggests that this is conceptually possible, but also highlights potential challenges arising from antigenic 
and HLA diversity. It remains to determined whether T cells are actively participating in the disease process or if 
they are merely responding to the death of neurons that release α-syn when they die. We hypothesize that α-syn-
specific T cells (or the specific TCRs) can potentially be used as a biomarker for early detection of PD (Fig. 5), 
and thereby earlier intervention. Furthermore, if it is proven that the T cells actively participate in the disease 
process and are involved in the neurodegeneration, we hypothesize that immunomodulatory interventions can 
be used to modify the specific T cell responses (Fig. 5).
In conclusion, this study provides a first characterization of α-syn-specific TCR clonotypes in individuals 
with PD. It is possible that further research that matches PD subjects of specific HLA alleles with antigen-specific 
TCRs, could provide as immunotherapeutics, diagnostics, and means to track longitudinal changes in the specific 
T cells and disease progression.
Methods
Ethics statement. All participants provided written informed consent for participation in the study. Ethi-
cal approval was obtained from the Institutional review boards at La Jolla Institute for Immunology (LJI; pro-
tocol numbers VD-118 and VD-124), University of Alabama (UAB; protocol number IRB-300001297), and 
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Columbia University Medical Center (CUMC; protocol number IRB-AAAQ9714). All research was performed 
in accordance with relevant guidelines and regulations.
Study subjects. We recruited a total of 20 participants with PD from the UAB Movement Disorders Clinic 
in Birmingham, Alabama and 55 age-matched healthy controls (HC) from the UAB Movement Disorders Clinic 
(n = 10), the Alzheimer’s disease research center at CUMC (n = 25), and Precision Med, a Contract Research 
Organization (n = 20). Cohort characteristics of PD and HC are listed in Table 1. Blood samples were collected 
by trained staff. The PD cohort was recruited from the clinical practice of the UAB Movement Disorders Clinic. 
Participants were enrolled by fellowship trained movement disorders specialists who identified subjects using 
the UK Parkinson’s Disease Society Brain Bank criteria for PD. All subjects had clinically moderate to advanced 
PD; 2 of three cardinal signs (rest tremor, rigidity, and/or bradykinesia); age at PD diagnosis 47–75, clear clinical 
evidence of dopaminergic medication benefit, age at enrollment 48–90, and ability to provide informed consent. 
The exclusion criteria included: atypical or secondary (i.e. medication-induced) parkinsonism or other neuro-
logical disorders; history of cancer within the past 3 years (except skin), known autoimmune disease (except 
thyroid), or chronic immune-modulatory therapy. Age-matched HC were selected on the basis of age and ability 
to provide informed consent. Exclusion criteria were the same as for PD donors, and in addition we excluded 
self-reported family history of PD in a first-degree relative.
The selection of PD participants for the TCR repertoire analysis was based on their response to α-syn and 
having sufficient numbers of available cells. The healthy controls were selected to be as closely matched to the 
PD cohort as possible i.e., recruited at the same site, same age and sex.
Peptides. Peptides were synthesized by A&A, LLC (San Diego, CA) as purified material (> 95% by reversed 
phase HPLC). α-Syn peptides were eleven 15-mers previously described as T cell  epitopes9, which were com-
bined into one α-syn peptide  pool10. These peptides represent the epitopes that were most frequently recognized 
by individuals with  PD9. PT peptides were 132 16-mers derived from B. pertussis antigens included in the aP vac-
cines (FHA, FIM2/3, PRN, and PT) from the Tohama I and 18,323  strains11,20. These were previously described 
as T cell epitopes recognized by more than 5% of wP or aP vaccinated  subjects11. The PT peptides were used as 
one peptide pool. Peptides were aliquoted in small volumes and stored at − 20 °C to avoid multiple freeze–thaw 
cycles.
PBMC isolation and in vitro expansion. Venous blood was collected in anticoagulant (e.g. heparin or 
EDTA)-containing blood bags or tubes. Peripheral blood mononuclear cells (PBMC) were purified from whole 
blood using Ficoll-PaqueTM density-gradient centrifugation, according to the manufacturer’s instructions (GE 
Healthcare Bio-Sciences, Pittsburgh, PA). Cells were suspended in FBS containing 10% (vol/vol) DMSO and 
cryopreserved in liquid nitrogen. For in vitro expansion, cryopreserved PBMCs were thawed in RPMI supple-
mented with 5% human serum (Gemini Bio-Products, West Sacramento, CA), 1% Glutamax (Gibco, Waltham, 
MA), 1% penicillin/streptomycin (Omega Scientific, Tarzana, CA) and 50 U/ml Benzonase (Millipore Sigma, 
Burlington, MA) as previously  described10. The cells were then washed and viability was evaluated using trypan 
blue dye exclusion. Briefly, at a density of 2 × 106 per mL, the cells were plated in each well of a 24 well plate in the 
presence of α-syn (5 μg/ml) or PT (2 μg/ml) peptide pool and were incubated in a 37 °C humidified  CO2 incuba-
tor for 2 weeks. Every 3–4 days, cells were supplied with 10 U/ml recombinant human IL-2.
After 14 days of culture, cells were harvested and used for Fluorospot assay (below) and TCR sequencing. 
Cells for TCR sequencing were pelleted and frozen at − 80 °C until further processing. The Fluorospot assay 
Figure 5.  The potential role of α-syn-specific T cells in PD pathogenesis. α-syn-specific T cell reactivity 
decrease as PD  progresses10, with the highest reactivity present pre-diagnosis of motor PD. α-syn-specific T 
cells can potentially be used as a biomarker for early detection and/or if they actively participate in the disease 
process as targets for early intervention.
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measured cytokine-specific reactivity against the different peptide pools. For TCR sequencing, the expanded 
cells were all harvested and pelleted, and so cells that may produce cytokines other than the ones measured in 
the Fluorospot assay were included as well.
Fluorospot assay. After 14 days of culture with α-syn or PT peptide pool, α-syn and PT-specific cellu-
lar responses were measured by IFNγ, IL-5 and IL-10 Fluorospot assay with all antibodies and reagents from 
Mabtech (Nacka Strand, Sweden), as previously  described10. Plates were coated overnight at 4 °C with an anti-
body mixture containing mouse anti-human IFNγ (clone 1-D1K), mouse anti-human IL-5 (clone TRFK5) and 
mouse anti-human IL-10 (clone 9D7). Briefly, 1 × 105 cells were added to each well of pre-coated Immobilon-FL 
PVDF 96-well plates (Mabtech) in the presence of 5 μg/ml peptide pool and incubated at 37 °C in humidified 
 CO2 incubator for 20–24 h. Cells from the in vitro culture stimulated with DMSO (corresponding to the per-
cent DMSO in the peptide pools) were used to assess non-specific/background cytokine production and PHA 
stimulation at 10 μg/ml was used as a positive control. All conditions were tested in triplicates. Fluorospot plates 
were developed according to manufacturer’s instructions (Mabtech). Briefly, cells were removed and plates were 
washed 6 times with 200 μl PBS/0.05% Tween 20 using an automated plate washer. After washing, 100 μl of anti-
body mixture containing anti-IFNγ (7-B6-1-FS-BAM), IL-5 (5A10-WASP), and IL-10 (12G8-biotin) prepared 
in PBS with 0.1% BSA was added to each well and plates were incubated for 2 h at room temperature. Plates 
were again washed 6 times with 200 μl PBS/0.05% Tween 20 using an automated plate washer and incubated 
with diluted fluorophores (anti-BAM-490, anti-WASP-640 and SA-550) for 1 h at room temperature. Finally, 
plates were once more washed 6 times with 200 μl PBS/0.05% Tween 20 using an automated plate washer and 
incubated with fluorescence enhancer for 15 min at room temperature. The plates were blotted dry and spots 
were counted by computer-assisted image analysis (AID iSpot, Aid Diagnostica GMBH, Strassberg, Germany). 
Responses were considered positive if the net spot-forming cells (SFC) per  106 PBMC were ≥ 100, the stimulation 
index ≥ 2, and p ≤ 0.05 by Student’s t-test or Poisson distribution test.
Isolation of CD4 T cells. On day one when PBMCs were thawed,  CD4+ T cells were isolated by nega-
tive selection using the CD4 purification T cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to manufacturer’s instructions. Briefly, PBMCs were incubated together with the biotin-antibody 
cocktail for 10 min at 4 °C and then with anti-biotin microbeads for 15 min at 4 °C. Unlabeled  CD4+ T cells 
were allowed to pass through the magnetic separation column. They were washed, pelleted, frozen and stored at 
− 80 °C until further processing.
HLA typing. Participants were HLA typed by an ASHI-accredited laboratory at Murdoch University (Insti-
tute for Immunology & Infectious Diseases, Western Australia) as previously  described10. HLA typing for class I 
(HLA A; B; C) and class II (DQA1; DQB1, DRB1 3,4,5; DPB1) was performed using locus-specific PCR ampli-
fication of genomic DNA. Patient-specific, barcoded primers were used for amplification. Amplified products 
were quantitated and pooled by subject and up to 48 subjects were pooled. An indexed (8 indexed MiSeq runs) 
library was then quantitated using Kappa universal QPCR library quantification kits. Sequencing was performed 
using an Illumina MiSeq using 2 × 300 paired-end chemistry. Reads were quality-filtered and passed through a 
proprietary allele calling algorithm and analysis pipeline using the latest IMGT HLA allele database as a refer-
ence. The algorithm was developed by E.P. and S.M. and relies on periodically updated versions of the freely 
available international immunogenetics information system (http://www.imgt.org) and an ASHI-accredited 
HLA allele caller software pipeline, IIID HLA Analysis suite (http://www.iiid.com.au/labor atory -testi ng/).
TCR sequencing. DNA was extracted from the cultured cells or ex vivo  CD4+ T cell samples using DNeasy 
Blood and Tissue kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. Samples were sent to 
Adaptive Biotechnologies (Seattle, WA) for TCRB sequencing according to their protocol. The ex vivo  CD4+ T 
cell samples were sequenced with “deep resolution” to cover a maximum number of clonotypes in the repertoire. 
Samples that were stimulated with peptide pools for 14 days and then harvested were sequenced with “survey 
resolution”. The identified CDR3 regions can be found in Dataset 1.
Data analysis. Pre-processing and quality control of the raw data was performed using the immunoSEQ 
analyzer (Adaptive Biotechnologies, Inc.). Measurement metrics of processed data were exported in the tsv file 
format and downstream data analysis was performed in Python v3.7.2 and in R v3.6.3. Only the productive rear-
rangements and the corresponding productive templates were considered for analysis. To identify clonotypes 
that were expanded in culture, each of the culture replicates for every donor was compared to the correspond-
ing ex vivo CD4 sample. p values and odds-ratios were calculated using a two-sided Fisher exact test, using the 
‘fisher exact’ function in the SciPy v1.3.025 and NumPy v1.16.126 extensions of Python. Clonotypes were consid-
ered significant if the -log2 odds ratios (OR) > 1 or < -1 and the false discovery rate (FDR) p value < 0.05, correct-
ing for multiple testing using the Benjamini–Hochberg  method27, and calculated using the ‘fdrcorrection’ func-
tion from the statsmodels module v0.9.028 for Python. For visualization purposes, all −log10 FDR p values > 50 
were set to 50. Sequence similarity by clustering was performed using GLIPH v1.0 with default parameters in 
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